Infantile-onset X-linked spinal muscular atrophy
MONDO:0010532A rare form of spinal muscular atrophy characterized by the neonatal onset of severe hypotonia, areflexia, profound weakness, multiple congenital contractures, facial dysmorphic features (myopathic face with open, tent-shaped mouth), cryptorchidism, and mild skeletal abnormalities (i.e. kyphosis, scoliosis), that is often preceded by polyhydramnios and reduced fetal movements in utero and followed by bone fractures shortly after birth. SMAX2 patients often have a limited life span, often succumbing to the disease within 2 years, as muscle weakness is progressive and chest muscle involvement eventually leads to ventilatory insufficiency and respiratory failure.
Also known as: SMAX2, X-linked distal arthrogryposis multiplex congenita, X-linked spinal muscular atrophy type 2, spinal muscular atrophy with arthrogryposis, spinal muscular atrophy, X-linked 2, infantile, X-linked recessive, spinal muscular atrophy, X-linked type 2, AMC, distal, X-linked, arthrogryposis multiplex congenita, distal, X-linked
29 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Could a zapping cap boost memory? small study tests brain stimulation for cognitive decline
Symptom relief Not yet recruitingThis pilot study will test whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve working memory in 30 adults with mild cognitive impairment or traumatic brain injury. Participants will receive low-level electrica…
Phase: NA • Sponsor: Sunnybrook Health Sciences Centre • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Gene therapy readiness check: new study maps virus immunity in muscle disease patients
Knowledge-focused Not yet recruitingThis study will test blood samples from 450 people aged 6 to 60 with inherited neuromuscular diseases to see if they have antibodies that could block gene therapy viruses (AAVs). The goal is to understand how common these antibodies are and which patients might be good candidates…
Phase: NA • Sponsor: Genethon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC